Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Immune Effector Cell Associated Neurotoxicity Syndrome”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Not applicableLooking for participantsNCT07390071
What this trial is testing

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Who this might be right for
LymphomaMyelomaCytokine Release Syndrome+1 more
University of Utah 40
Testing effectiveness (Phase 2)Looking for participantsNCT06421675
What this trial is testing

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
Ontario Clinical Oncology Group (OCOG) 40
Not applicableLooking for participantsNCT05643092
What this trial is testing

Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome

Who this might be right for
Immune Effector Cell Associated Neurotoxicity Syndrome
zhang shoulong 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07567014
What this trial is testing

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

Who this might be right for
Multiple MyelomaLarge B-cell Lymphoma (LBCL)
NYU Langone Health 60
Early research (Phase 1)Not Yet RecruitingNCT07166549
What this trial is testing

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Who this might be right for
B Cell MalignanciesB-cell LeukemiaB Cell Lymphoma+2 more
University Hospital, Basel, Switzerland 12
Not applicableStudy completedNCT05040230
What this trial is testing

EEG Encephalopathy Patterns in Immune Effectors Cells-associated Neurotoxicity Syndrome (ICANS)Lay Language

Who this might be right for
Immune Effector Cell EncephalopathyNeurotoxicity
University Hospital, Montpellier 40
Post-approval studies (Phase 4)Looking for participantsNCT06706102
What this trial is testing

Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence of Immune Effector Cell-Associated Neurotoxicity Syndrome

Who this might be right for
Immune Effector Cell Associated Neurotoxicity Syndrome
Centre Hospitalier Universitaire de Saint Etienne 60
Testing effectiveness (Phase 2)Looking for participantsNCT07106671
What this trial is testing

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Who this might be right for
CRS - Cytokine Release SyndromeMyeloma
Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)Study completedNCT04975555
What this trial is testing

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Who this might be right for
Cytokine Release SyndromeICANSLymphoma, Non-Hodgkin+2 more
University of Alabama at Birmingham 20
Testing effectiveness (Phase 2)WithdrawnNCT06703216
What this trial is testing

Pre-emptive Anakinra for Cytokine Event Reduction

Who this might be right for
B-Acute Lymphoblastic LeukemiaCAR-T Cell TherapyCytokine Release Syndrome+2 more
Kevin McNerney
Testing effectiveness (Phase 2)WithdrawnNCT06352866
What this trial is testing

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Who this might be right for
Multiple MyelomaCytokine Release SyndromeRefractory Multiple Myeloma+1 more
Jack Khouri, MD
Not applicableNot Yet RecruitingNCT07403812
What this trial is testing

Assessing DCog Short for Neurotoxicity in CAR-T

Who this might be right for
NeurotoxicityNeurotoxicity SyndromesHematologic Malignancy+1 more
Beth Israel Deaconess Medical Center 40
Testing effectiveness (Phase 2)Study completedNCT04071366
What this trial is testing

Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Who this might be right for
Cytokine Release Syndrome
Incyte Corporation 112
Testing effectiveness (Phase 2)Looking for participantsNCT05972135
What this trial is testing

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Who this might be right for
Multiple Myeloma
SCRI Development Innovations, LLC 100
Not applicableStudy completedNCT05510596
What this trial is testing

Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome

Who this might be right for
Lymphoma, B-CellNeurotoxicity
University Hospital, Montpellier 25
Early research (Phase 1)Looking for participantsNCT07169487
What this trial is testing

Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study

Who this might be right for
Cytokine Release SyndromeICANS
Institute of Hematology & Blood Diseases Hospital, China 18